Indications and Usage:
GASTROGRAFIN (diatrizoate meglumine and diatrizoate sodium solution USP) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous.
GASTROGRAFIN (diatrizoate meglumine and diatrizoate sodium solution USP) may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.
IMPORTANT SAFETY INFORMATION:
Not for parenteral use; do not inject. For oral or rectal administration only. It should be kept in mind that serious or anaphylactoid reactions that may occur with intravascular administration of radiopaque contrast agents are theoretically possible following administration by other routes. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever and food allergies).
Please see full Prescribing Information for GASTROGRAFIN (diatrizoate meglumine and diatrizoate sodium solution USP) by clicking here.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
GASTROGRAFIN is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831, by Therapex, Division of E-Z-EM Canada, Inc., Anjou, Quebec, Canada.
GASTROGRAFIN is a registered trademark of Bracco Diagnostics Inc.